Table 3.

Factors associated with secondary non-depletion non-response to rituximab (2NDNR)

Characteristics prior to rituximab retreatment	Continued to respond (n=61)	2NDNR (n=9)	p Value
Concomitant IS, N (%)	41 (67)	2 (22)	0.023
Prednisolone, median (IQR) mg	5 (0–10)	5 (0–17.5)	0.729
Duration of response, median (IQR) weeks	50 (36–107)	62 (52–164)	0.239
Total BILAG score, median (IQR)	16 (12–21)	24 (12–27)	0.209
Partial clinical response in cycle 1, N (%)	24 (39)	3 (33)	0.731
Naïve B-cells, median (IQR) 109 cells/L	0.0349 (0.0071–0.0735)	0.0620 (0.0101–0.0950)	0.296
Memory B-cells, median (IQR) x 109/L	0.0019 (0.0010–0.0047)	0.0090 (0.0054–0.0394)	0.175
Plasmablasts, median (IQR) x 109/L	0.0011 (0.0004–0.0036)	0.0086 (0.0052–0.0227)	<0.001

*NDNR, secondary non-depletion and non-response; IS, immunosuppressant.